Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.
Eur J Med Res
; 27(1): 68, 2022 May 15.
Article
in English
| MEDLINE | ID: covidwho-1849783
ABSTRACT
BACKGROUND:
Dermatomyositis is a rare idiopathic inflammatory disease with diverse presentations that can have varying degrees of cutaneous and systemic involvement. This phenotypic heterogeneity makes DM a therapeutic challenge. Some therapeutic drugs, such as hormones and immunosuppressants, have poor therapeutic effects. In recent years, tofacitinib has been reported to be effective in the treatment of dermatomyositis. CASE PRESENTATION We report a case of anti-MDA5 antibody-positive dermatomyositis that was relieved after treatment with tofacitinib, during which gallbladder gangrene and suppurative cholecystitis occurred. After cholecystectomy, we continued to use tofacitinib and achieved a good therapeutic effect.CONCLUSIONS:
Tofacitinib is effective in the treatment of anti-MDA5 antibody-positive dermatomyositis, but the risk of infection is increased. It can still be used after infection control. Close follow-up should be performed during the use of tofacitinib.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cholecystitis
/
Lung Diseases, Interstitial
/
Dermatomyositis
Type of study:
Case report
/
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur J Med Res
Journal subject:
Medicine
Year:
2022
Document Type:
Article
Affiliation country:
S40001-022-00693-0
Similar
MEDLINE
...
LILACS
LIS